Leukodepletion and aprotinin improve clinical outcome after extracorporeal circulation.

Gott, J P

Gott, J P.

Affiliation

Gott JP; Fuqua Heart Center, Piedmount Hospital, Atlanta, Georgia 30309, USA. gottjp@aol.com

Perfusion ; 16 Suppl: 5-9, 2001 Mar.

Article in En | MEDLINE | ID: mdl-11334206

Subject(s)

Aprotinin/pharmacology; Extracorporeal Circulation/standards; Leukapheresis; Serine Proteinase Inhibitors/pharmacology; Adrenal Cortex Hormones/administration & dosage; Antifibrinolytic Agents/administration & dosage; Antifibrinolytic Agents/economics; Antifibrinolytic Agents/pharmacology; Aprotinin/administration & dosage; Aprotinin/economics; Cardiopulmonary Bypass/adverse effects; Cardiopulmonary Bypass/economics; Cardiopulmonary Bypass/methods; Cardiopulmonary Bypass/mortality; Coated Materials, Biocompatible; Costs and Cost Analysis; Extracorporeal Circulation/economics; Extracorporeal Circulation/mortality; Fibrin Fibrinogen Degradation Products/metabolism; Filtration; Heparin; Humans; Inflammation/drug therapy; Inflammation/etiology; Inflammation/prevention & control; Serine Proteinase Inhibitors/administration & dosage; Serine Proteinase Inhibitors/economics; Treatment Outcome

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Serine Proteinase Inhibitors / Aprotinin / Leukapheresis / Extracorporeal Circulation Type of study: Clinical_trials / Etiology_studies / Health_economic_evaluation Limits: Humans Language: En Journal: Perfusion Journal subject: CARDIOLOGIA Year: 2001 Document type: Article Affiliation country: United States Country of publication: United kingdom

Search on Google

Add to My VHL

XML

PubMed Links